Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Cucurbitacine and ibrutinib composite for treating breast cancer

A technology of ibrutinib and cucurbitacin, applied in the field of medicine, can solve the problems of easy invasion and metastasis, high mortality, poor treatment prognosis, etc., and achieve the effects of significant synergistic efficacy, broad application prospects, and guaranteed safety.

Active Publication Date: 2020-07-17
DELI WEI BEIJING BIOLOGICAL TECH
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

TNBC is a special subtype of breast cancer. Tumor cells lack effective targets of ER, PR and HER-2, so far there is no better treatment plan
Triple-negative breast cancer is generally treated according to the conventional targeted standard treatment of breast cancer, but the prognosis is poor, and invasion and metastasis are prone to occur, which seriously endangers the life of patients and has a high mortality rate
There is no research on the combination of cucurbitacin B and ibrutinib for breast cancer, especially triple-negative breast cancer. The development of the combination of these two drugs can provide a new treatment method for patients with such diseases, and also provide a new way for other patients. Combinations of drugs offer new research strategies

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cucurbitacine and ibrutinib composite for treating breast cancer
  • Cucurbitacine and ibrutinib composite for treating breast cancer
  • Cucurbitacine and ibrutinib composite for treating breast cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Embodiment 1 injection

[0025] prescription:

[0026] Ibrutinib 40mg

[0027] F68 1000mg

[0028] Add sterile water for injection to 5ml

[0029] Preparation method: Put the prescribed amount of ibrutinib and F68 in a beaker, add an appropriate amount of ethanol and heat to dissolve, inject sterile water for injection under magnetic stirring, adjust the volume to 5ml, and obtain.

Embodiment 2

[0030] Embodiment 2 injection

[0031] prescription:

[0032] Cucurbitacin B 1mg

[0033] F68 1000mg

[0034] Add sterile water for injection to 5ml

[0035] Preparation method: put cucurbitacin B and F68 with a purity greater than 99% in a prescription amount into a beaker, add appropriate amount of ethanol and heat to dissolve, inject sterile water for injection under magnetic stirring, adjust the volume to 5ml, and obtain.

Embodiment 3

[0036] Embodiment 3 injection

[0037] prescription:

[0038]

[0039] Preparation method: put the prescribed amount of ibrutinib, cucurbitacin B and F68 with a purity greater than 99% in a beaker, add an appropriate amount of ethanol and heat to dissolve, inject sterile water for injection under magnetic stirring, adjust the volume to 5ml, and obtain .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a medicine composite for treating breast cancer, particularly triple negative breast cancer. The composite comprises cucurbitacine and ibrutinib. The invention further relatesto a use of the combination of the cucurbitacine and the ibrutinib in the preparation of medicines for treating triple negative breast cancer. The combination of the cucurbitacine and the ibrutinib has a significant synergistic curative effect in the treatment of breast cancer, especially triple negative breast cancer. The composite brings new hope for breast cancer patients, provides scientificbasis for research and development of novel antitumor medicines, and has a promising application prospect.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a pharmaceutical composition comprising cucurbitacin and ibrutinib and its application in treating breast cancer, especially triple-negative breast cancer. Background technique [0002] Breast cancer ranks first in the mortality rate of female malignant tumors in my country. Triple negative breast cancer (TNBC) is a combination of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (human epidermal growth factor receptor 2, HER-2) All showed negative breast cancer, accounting for 15% of breast cancer incidence. TNBC is a special subtype of breast cancer. Tumor cells lack effective targets of ER, PR and HER-2, and there is no better treatment plan so far. Triple-negative breast cancer is generally treated according to the conventional targeted standard treatment of breast cancer, but the prognosis of treatment is poor, and...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/575A61K31/519A61P15/14A61P35/00
CPCA61K31/575A61K31/519A61P15/14A61P35/00A61K2300/00
Inventor 吴莹邓意辉邓吉林
Owner DELI WEI BEIJING BIOLOGICAL TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com